Src Inhibitor Active Against Osteoporosis.(Brief Article)(Statistical Data Included)

In a paper published in the August, 15, 2000 issue of the Proceedings of the National Academy of Sciences, USA, Ariad Pharmaceutical (26 Landsdowne St., Cambridge, MA 02139; Tel: 617/494-0400, Fax: 617/494-8144) scientists demonstrated that a small-molecule drug, which directly inhibits the Src tyrosine kinase, is effective in vivo in an animal model of osteoporosis.

Src has been validated as a therapeutic target for osteoporosis by gene knockout studies in animals and other genomics techniques. Deleting or blocking the Src …